Literature DB >> 11544371

Antigenic variation at the infected red cell surface in malaria.

S Kyes1, P Horrocks, C Newbold.   

Abstract

Many pathogens that either rely on an insect vector to complete their life cycle (e.g., Trypanosoma spp. and Borrelia spp.) or exist in a unique ecological niche where transmission from host to host is sporadic (e.g., Neisseria spp.) have evolved strategies to maintain infection of their mammalian hosts for long periods of time in order to ensure their survival. Because they have to survive in the face of a fully functional immune system, a common feature of many of these organisms is their development of sophisticated strategies for immune evasion. For the above organisms and for malaria parasites of the genus Plasmodium, a common theme is the ability to undergo clonal antigenic variation. In all cases, surface molecules that are important targets of the humoral immune response are encoded in the genome as multicopy, nonallelic gene families. Antigenic variation is accomplished by the successive expression of members of these gene families that show little or no immunological cross-reactivity. In the case of malaria parasites, however, some of the molecules that undergo antigenic variation are also major virulence factors, adding an additional level of complication to the host-parasite interaction. In this review, we cover the history of antigenic variation in malaria and then summarize the more recent data with particular emphasis on Plasmodium falciparum, the etiological agent of the most severe form of human malaria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544371     DOI: 10.1146/annurev.micro.55.1.673

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  147 in total

1.  Small variant STEVOR antigen is uniquely located within Maurer's clefts in Plasmodium falciparum-infected red blood cells.

Authors:  M Kaviratne; S M Khan; W Jarra; P R Preiser
Journal:  Eukaryot Cell       Date:  2002-12

2.  Immune characterization of Plasmodium falciparum parasites with a shared genetic signature in a region of decreasing transmission.

Authors:  Amy K Bei; Ababacar Diouf; Kazutoyo Miura; Daniel B Larremore; Ulf Ribacke; Gregory Tullo; Eli L Moss; Daniel E Neafsey; Rachel F Daniels; Amir E Zeituni; Iguosadolo Nosamiefan; Sarah K Volkman; Ambroise D Ahouidi; Daouda Ndiaye; Tandakha Dieye; Souleymane Mboup; Caroline O Buckee; Carole A Long; Dyann F Wirth
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

Review 3.  Understanding naturally acquired immunity to Plasmodium falciparum malaria.

Authors:  D J Roberts
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 4.  Repetitive elements in genomes of parasitic protozoa.

Authors:  Bill Wickstead; Klaus Ersfeld; Keith Gull
Journal:  Microbiol Mol Biol Rev       Date:  2003-09       Impact factor: 11.056

5.  Variable var transition rates underlie antigenic variation in malaria.

Authors:  Paul Horrocks; Robert Pinches; Zóe Christodoulou; Sue A Kyes; Chris I Newbold
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-15       Impact factor: 11.205

6.  The effects of symmetry on the dynamics of antigenic variation.

Authors:  Konstantin B Blyuss
Journal:  J Math Biol       Date:  2013-01       Impact factor: 2.259

Review 7.  Maurer's clefts, the enigma of Plasmodium falciparum.

Authors:  Esther Mundwiler-Pachlatko; Hans-Peter Beck
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-27       Impact factor: 11.205

8.  Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study.

Authors:  Mirjam Kaestli; Ian A Cockburn; Alfred Cortés; Kay Baea; J Alexandra Rowe; Hans-Peter Beck
Journal:  J Infect Dis       Date:  2006-04-20       Impact factor: 5.226

Review 9.  Antimalarial drug resistance.

Authors:  Nicholas J White
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.